Owen Mumford is pleased to announce that our leading sustainability program, ReSCiD (Remanufacturing for a Sustainable Future in Combination Injection Devices), has made it to the final interview stage of the prestigious Innovate UK Sustainable Medicines Manufacturing Grand Challenge.
ReSCiD tackles a major environmental issue in the pharmaceutical field: the widespread use of single-use combination injection devices. These devices, which are critical for offering advanced treatments, add significantly to clinical waste and carbon emissions.
Our goal is to shift to a circular system where devices can be returned, safely taken apart, cleaned, and remanufactured for reuse – a game-changing move for the industry.
This project unites a strong group of 18 partners, including top universities, pioneering small and medium businesses, NHS collaborators, and international specialists. Together, we plan to:
– Develop scalable remanufacturing techniques
– Create digital systems for tracking
– Work with regulators to set new standards
– Prove real-world success through pilot studies
For over 70 years, Owen Mumford has led the way in medical technology and was one of the first device companies in the world to earn B Corp certification. We are committed to driving positive change in our field – setting the example, promoting innovation, and helping build a healthier and more sustainable future for everyone.
Our ReSCiD program could not only help the NHS achieve its Net Zero goals, but also make the UK a world leader in sustainable medical device development.
We are excited for the next steps and thank Innovate UK for recognizing the value of this innovative program.